Schimmel Paul's Form 4 filing
aTYR PHARMA INCATYR · filed May 11, 2023
- Accession no.
- 0001209191-23-028607
- Filed
- May 11, 2023
- Trade date
- May 10, 2023
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $450.0K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Schimmel PaulCIK 0001236447 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 10, 2023 | Common Stock | PPurchaseAcquired | +200,000 | $2.25F1 | +$450,000 | 313,023 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents weighted average price for the shares. The shares were purchased ranging from $2.245 to $2.25 per share under the issuer's "at-the-market" offering program implemented pursuant to the issuer's Open Market Sale Agreement with Jefferies LLC. The reporting person will provide to the Securities and Exchange Commission staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares purchased at each separate price.
Referenced by the price of 1 transaction in Table I.